Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

M&A Pressure Mounts For Merck & Co After Alzheimer's Drug Dismissed

Executive Summary

Merck's verubecestat has flopped in a second Phase III Alzheimer's trial; investors are anticipating M&A or licensing deals soon to bring something new into the big pharma's development portfolio.

You may also be interested in...



Novartis/Amgen End CNP520 Studies, Leaving Eisai/Biogen With Last BACE Inhibitor In The Clinic

An interim look at two Phase II/III trials showed the drug worsened cognition in people at high risk of developing Alzheimer's disease. This is the 16th failure of a BACE-targeting therapy.

After Abeta Blow, Biogen And Eisai Get BACE Boost

Elenbecestat can continue in the Phase III MISSION AD studies in Alzheimer’s, the data safety monitoring board says.

Why Biogen/Eisai's Aducanumab Failure Is Not The End Of Amyloid Hypothesis

Biogen and Eisai still have multiple programs testing amyloid-targeting therapies in the treatment of Alzheimer's disease, but pressure for Biogen to focus its efforts elsewhere are mounting after the partners discontinued Phase III studies for aducanumab.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel